Psychiatric Disorders: ATX-inhibiting drugs as a new therapeutic option: Proof-of-Concept

Project Information

PsychAID

Grant agreement ID: 811385

DOI

10.3030/811385

Project closed

EC signature date 26 October 2018

Start date 1 January 2019

End date 31 December 2020

Funded under

• EXCELLENT SCIENCE - European Research Council (ERC)

Total cost

€ 149 375,00

EU contribution

€ 149 375,00

Coordinated by

UNIVERSITAET MUENSTER
Germany

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Peer reviewed articles (1)

Correction: Synaptic phospholipids as a new target for cortical hyperexcitability and E/I balance in psychiatric disorders

Author(s): Carine Thalman, Guilherme Horta, Lianyong Qiao, Heiko Endle, Irmgard Tegeder, Hong Cheng, Gregor Laube, Torfi Sigurdsson, Maria Jelena Hauser, Stefan Tenzer, Ute Distler, Junken Aoki, Andrew J. Morris, Gerd Geisslinger, Jochen Röper, Sergei Kirischuk, Heiko J. Luhmann, Konstantin Radyushkin, Robert Nitsch, Johannes Vogt
Published in: Molecular Psychiatry, Issue 25/11, 2020, Page(s) 3108-3108, ISSN 1359-4184
Publisher: Nature Publishing Group
DOI: 10.1038/s41380-018-0320-1

Intellectual Property Rights

Patent (1)

LPA LEVEL REDUCTION FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS

Application/Publication number: 16 787728
Date: 2016-10-21
Applicant(s): UNIVERSITAET MUENSTER